56019-64-8

Basic information

• Product Name: 1-(6-METHYL-PYRIDIN-3-YL)-ETHANOL
• Synonyms: 1-(6-METHYL-PYRIDIN-3-YL)-ETHANOL
• CAS NO: 56019-64-8
• Molecular Formula: C₈H₁₁NO
• Molecular Weight: 137.18
• Mol File: 56019-64-8.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(6-METHYL-PYRIDIN-3-YL)-ETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(6-METHYL-PYRIDIN-3-YL)-ETHANOL(56019-64-8)
• EPA Substance Registry System: 1-(6-METHYL-PYRIDIN-3-YL)-ETHANOL(56019-64-8)

Safety Data

• Hazardous Substances Data: 56019-64-8(Hazardous Substances Data)

Usage

Synonyms

6-MPE

Chemical Class

Pyridine derivative

Physical State

Colorless liquid

Odor

Faint

Solubility

Soluble in organic solvents

Pharmaceutical industry

Intermediate for the synthesis of various pharmaceuticals.

Agrochemicals

Intermediate for the synthesis of agrochemicals.

Fine chemicals

Intermediate for the synthesis of other fine chemicals.

Skin contact

May cause irritation.

Eye contact

May cause irritation.

Inhalation

May cause harmful effects to the respiratory system.

Handling

Handle with care to avoid contact with skin, eyes, or respiratory system.

Upstream product

• 75-16-1 methylmagnesium bromide 
• 544-97-8 dimethyl zinc(II) 
• 140-76-1 2-methyl-5-vinylpyridine 
• 2024-89-7 5-ethyl-2-methyl-pyridine; hydrochloride 
• 36357-38-7 1-(6-methyl-pyridin-3-yl)-ethanone 
• 104-90-5 5-ethyl-2-methyl-pyridine 
• 21683-58-9 ethyl 3-(2-methyl-5-pyridinyl)-3-oxopropanoate 
• 5470-70-2 Methyl 6-methylnicotinate 

Downstream Products

• 146062-44-4 Hydroxypioglitazone 
• 184766-25-4 4-{2-[5-(1-methoxymethoxy-ethyl)-pyridin-2-yl]-ethoxy}benzaldehyde 
• 184766-39-0 5-(4-(2-(5-(1-(methoxymethoxy)ethyl)pyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione 
• 146062-59-1 5-(1-methoxymethoxyethyl)-2-<2-(4-nitrophenoxy)ethyl>pyridine 
• 146062-45-5 Ketopioglitazone 
• 1026292-59-0 2-Imino-5-(4-{2-[5-(1-methoxymethoxy-ethyl)-pyridin-2-yl]-ethoxy}-benzyl)-thiazolidin-4-one 
• 146062-60-4 methyl 2-bromo-3-<4-<2-<5-(1-memthoxymethoxyethyl)-2-pyridyl>ethoxy>phenyl>propionate 
• 104-89-2 5-ethyl-2-methylpiperidine 
• 36357-38-7 1-(6-methyl-pyridin-3-yl)-ethanone 
• 146062-57-9 3-(1-(methoxymethoxy)ethyl)-6-methylpyridine 

Relevant articles and documents

PROCESS FOR PREPARING 5-[[4-[2-[5-(1-HYDROXYETHYL)-2-PYRIDINYL]ETHOXY]PHENYL]METHYL]-2,4-THIAZOLIDINEDIONE AND SALTS THEREOF

The disclosure provides a process of making the compound of Formula I, and pharmaceutically acceptable salts thereof: and the process of making the intermediate of Formula III: wherein PG is as defined as set forth in the specification.

2,4-THIAZOLIDINEDIONE DERIVATIVES IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS

The present invention provides 5-(4-(2-(5-(1-hydroxyethyl)pyridine-2-yl)ethoxy) benzyl)thiazolidine-2,4-dione and novel stereoisomers of said compound for use in the treatment of central nervous system (NS) disorders.

Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone

Pioglitazone (5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4- thiazolidinedione, 2) is a prototypical antidiabetic thiazolidinedione that had been evaluated for possible clinical development. Metabolites 6-9 have been identified after dosing of rats and dogs. Ketone 10 has not yet been identified as a metabolite but has been added to the list as a putative metabolite by analogy to alcohol 6 and ketone 7. We have developed improved syntheses of pioglitazone (2) metabolites 6-9 and the putative metabolite ketone 10. These entities have been compared in the KKA(y) mouse model of human type-II diabetes to pioglitazone (2). Ketone 10 has proven to be the most potent of these thiazolidinediones in this in vivo assay. When 6-10 were compared in vitro in the 3T3-L1 cell line to 2, for their ability to augment insulin-stimulated lipogenesis, 10 was again the most potent compound with 6, 7, and 9 roughly equivalent to 2. These data suggest that metabolites 6, 7, and 9 are likely to contribute to the pharmacological activity of pioglitazone (2), as had been previously reported for ciglitazone (1).